FDA seeks soy comments
This article was originally published in The Tan Sheet
Executive Summary
FDA wants to extend the current record retention requirements for health claims related to soy proteins and the risk of coronary heart disease, according to a request for comment in the Oct. 22 Federal Register. Currently, FDA requires firms making these health claims to provide upon request records verifying the amount of soy protein per serving, other protein sources, ingredient purchase orders and other information. FDA estimates it will take firms one hour to collect this information
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.